Presepsin in the Diagnosis of Sepsis in Critically Ill Patients
- Conditions
- InfectionSepsis
- Interventions
- Diagnostic Test: Presepsin measurement
- Registration Number
- NCT03584594
- Lead Sponsor
- University Hospital Ostrava
- Brief Summary
Sepsis is one of the most common causes of death worldwide. It is caused by a complex of inadequate host responses to infection. Sepsis remains a major challenge of modern intensive care medicine. Despite recent improvements, the incidence of sepsis in critically ill patients increases steadily (25%) and mortality rates remain unacceptably high (30%). It is difficult to distinguish the sepsis from the non-infectious systemic inflammatory response syndrome. Early identification of the origin of infection can help dramatically to improve outcome and reduce mortality. That is why clinicians need fast, reliable and specific biomarkers for sepsis recognition.
- Detailed Description
Comparison between the detection of novel early inflammatory biomarker (PSEP) and the others normally used biomarkers (c-reactive protein - CRP, interleukin 6 - IL6, procalcitonin - PCT) in the early diagnosing of sepsis in the critically ill patients A broad range of clinical and laboratory parameters are combined (Surviving sepsis campaign, international guidelines) for early sepsis identification: white blood cells (WBC), C-reactive protein (CRP), interleukin 6 (IL-6), procalcitonin (PCT).
An ideal biomarker should be a fast and specific increase in sepsis, short half-life, rapid decrease after administration of an effective therapy and fast (bed-side) method of determination. None of the current biomarkers have all of these characteristics.
We investigate the diagnostic accuracy of presepsin compared to other biomarkers (WBC, PCT, IL6, CRP) for infection or sepsis, defined according to Sepsis-3 definition (Singer, JAMA 2016) in adult patients admitted to ICU with suspected sepsis.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
- signed informed consent
- diagnosis of sepsis from qSOFA (quick Subsequent Organ Failures Assessment)
- need of vasopressors for mean arterial pressure (MAP) ≥ 65 mmHg
- lactate levels ≥ 2mmol/l despite adequate volume resuscitation
- age below 18 years
- terminal state of disease
- pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Presepsin assessment Presepsin measurement Residual blood samples after performing all necessary blood examinations and analyses will be used to determine the level of presepsin, as the potential new biomarker of infection.
- Primary Outcome Measures
Name Time Method Serum concentration of Presepsin 47 months Serum concentration of Presepsin in patients with sepsis or septic shock will be compared to PCT, IL6 and CRP results.
Area under the Receiver-operating characteristic Curve 47 months Area under the Receiver-operating characteristic Curve (ROC-AUC) of the presepsin and other biomarkers (PCT, IL6, CRP) for diagnostic value of any biomarker will be analysed on a scale 0-100.
- Secondary Outcome Measures
Name Time Method Correlation of serum concentration of presepsin with detection of microbial agents 47 months Comparison of presepsin concentration in serum with the results of culture/microscopy of a pathogen from a clinical focus using methods of classical microbiology. In patients with risk factors for invasive mycosis, comparison of presepsin concentration with serum for galactomannan (GM) and beta- D- glucan (BG) detection will be performed.
Trial Locations
- Locations (2)
Public Health Institute Ostrava
🇨🇿Ostrava, Moravian-Silesian Region, Czechia
University Hospital Ostrava
🇨🇿Ostrava, Moravian-Silesian Region, Czechia